Flanders Attends Health Management Forum of Tianjin Health Association
Release time:
2020-07-22
Flanders Attends Tianjin Health Association Health Management Forum
News 12# July 14 , "Healthy China We Are Acting"-the 10th Anniversary Health Management Forum of Tianjin Health Management Association, sponsored by Tianjin Health Management Association, Tianjin Medical Association Health Management Branch and Beijing-Tianjin-Hebei Health Promotion Industry Alliance, was held in Tianjin. Tianjin Jianfeng Flanders Company participated in the conference as a member unit.
This conference takes "Healthy China We Are Acting" as the theme, and closely focuses on the central government's central goal of "No Health for All People, No Well-off for All People", and incorporates the blueprint of Healthy China's work and chronic disease prevention and control into Long-term planning, promote the development of the health service industry and the large health industry, carry out health management activities, improve the health literacy of the whole people, and promote the sustainable development of the health management industry, the development of big health industry and the construction of health management discipline are discussed in depth.
As a member unit, Flanders was invited to participate in the conference and presented a series of healthy foods to the participating experts, which was deeply loved by the participating experts and representatives. Flanders is also the only company approved to present products at this conference, using high-quality health products and advanced production technology as a medium to discuss and communicate with experts in the health management industry.
In recent years, obesity and chronic diseases have become the main reasons affecting people's health, and unreasonable diet is the main culprit of obesity and chronic diseases. Flemish's products are designed to focus on a reasonable diet and shape a healthy body, combined with modern and standardized products and services and corporate management models, aiming to build themselves into a more influential healthy enterprise. Flanders has made continuous efforts in the areas of "prevention before disease, prevention of chronic disease, and prevention of recovery after healing", and has developed a full-nutrition special diet, functional food and individualized nutrition intervention food suitable for obese people and sports people. These products will affect the health and quality of life of the masses in a wider and deeper range.
This meeting embodies the consistent concept of the coordinated development of the health management industry in Beijing, Tianjin and Hebei. Flanders adheres to the promotion of health services as its own responsibility, and strives to promote and maintain the health and quality of life of the broad masses of people. to contribute more to the construction of a healthy China. (Liu Hairong)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page